Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

Slimjaro Emerges as the Leading Natural Mounjaro Recipe for Weight Loss in 2025—Delivering a Powerful OTC Tirzepatide ...

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Discover the effectiveness and safety of Mounjaro, the new weight loss drug launched in India. Learn from expert Dr. Pal ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Researchers note many people first hearing of new drugs via social media, increasing the risk of the spread of disinformation ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

Multiple randomised controlled trials have demonstrated that treatment with glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIP RAs) lead to ...